A Clinical Study on the Safety and Efficacy of Chimeric Antigen Receptor T-cell Therapy for the TM4SF1- and EpCAM-positive Recurrent/Refractory Solid Tumors

Transmembrane 4 L Six Family Member 1 (TM4SF1) and Epithelial cell adhesion molecule (EpCAM) are both highly expressed in many epithelial-derived solid tumors.
The Chimeric Antigen Receptor T-cells (CAR-T) that target TM4SF1 or EpCAM have been generated respectively in our good manufacturing practices (GMP) facility and their anti-tumor effects have been demonstrated in multiple in vitro and in vivo studies.
Clinical studies are proposed here to evaluate the anti-tumor activity of these cell therapy products for treatment of patients with TM4SF1 or EpCAM positive tumors. In this study, the safety, tolerance, and preliminary efficacy of CART-TM4SF1 and CART-EpCAM cells will be examined inpatients with refractory/recurrent advanced pancreatic cancer, colorectal cancer, gastric cancer or lung cancer. And 9 patients for each cancer will be evaluated.
Clinical and immunological responses will be evaluated about 30 days and last up to 2 years after CAR-T cell infusion.

开始日期2019-11-20

申办/合作机构

Tangdu Hospital

[+1]

100 项与 Anti-EPCAM CAR-T-cell therapy (Shanghai Biomed-union Biotechnology) 相关的临床结果

登录后查看更多信息

100 项与 Anti-EPCAM CAR-T-cell therapy (Shanghai Biomed-union Biotechnology) 相关的转化医学

登录后查看更多信息

100 项与 Anti-EPCAM CAR-T-cell therapy (Shanghai Biomed-union Biotechnology) 相关的专利（医药）

登录后查看更多信息

项与 Anti-EPCAM CAR-T-cell therapy (Shanghai Biomed-union Biotechnology) 相关的文献（医药）

2023-12-01·Human Gene Therapy

Chimeric Antigen Receptor-T Cell Therapy Decreases Distant Metastasis and Inhibits Local Recurrence Post-surgery in Mice

Article

作者: Wang, Fengling ; Jiang, Lin ; Huang, Yong ; Tan, Shisheng ; Li, Jing ; Xu, Qing ; Zhang, Yalan ; Guo, Xianling ; Yang, Yuening ; Yan, Feiyang ; Li, Jiaqian ; Wang, Wei ; Yang, Jinrong ; Li, Dan ; Wei, Yu-Quan ; Zhou, Weilin ; Gao, Haozhan

Distant metastasis and primary tumor relapse are the two main hurdles to the success of surgical treatment for cancer patients. Circulating tumor cells (CTCs) and incomplete surgical resection are the primary cause of distant metastasis and local recurrence of tumors, respectively. Chimeric antigen receptor (CAR)-modified T cells target residual carcinomas and CTCs hold the potential to inhibit primary recurrence and reduce tumor metastasis, but the experimental evidence is lacking. Here, we developed a surgery-induced tumor metastasis model in immunocompetent mice to investigate the efficacy of CAR-T cells therapy in preventing metastasis and local recurrence. We observed that subcutaneous tumor resection has induced a large number of CTCs intravasated into circulation. EpCAM-specific CAR-T was effective in clearing CTCs following surgical removal of the tumor. This resulted in less pulmonary metastasis and longer survival in mice when compared to mice treated with surgery followed by Mock-T cells infusion. In addition, the local relapse was obviously inhibited at the surgical site followed by EpCAM-CAR-T cell treatment. This study demonstrated that CAR-T cell therapy can be an adjuvant treatment following surgery to prevent tumor metastasis and inhibit primary tumor relapse for cancer patients.

100 项与 Anti-EPCAM CAR-T-cell therapy (Shanghai Biomed-union Biotechnology) 相关的药物交易

登录后查看更多信息